Prøve GULL - Gratis

When Clinical Trials Suffer From 'Complicated' Interactions

BioSpectrum Asia

|

BioSpectrum Asia Feb 2025

Diversity in culture, language, and data gathering methods will further increase the difficulty of clinical trials as they become more international, particularly with the growing number of sites being employed across China, Japan, South Korea, and India.

When Clinical Trials Suffer From 'Complicated' Interactions

Dr Christine Senn, Senior Vice President, Site-Sponsor Innovation, Advarra

Clinical trial management involves several scientific, commercial, and practical requirements that the industry will continue to struggle to satisfy without more cooperation across research sites, sponsors, and stakeholders. The need for better site-sponsored-CRO coordination will only increase as clinical trials continue to become more complicated.

When almost half of clinical trial stakeholders describe their working relationships as "complicated," it's a sign that something needs to change.

That sentiment was one of several findings that came to light with Advarra's recent industry survey of more than 200 stakeholders across the clinical research ecosystem. The results, which included responses from clinical research sites, sponsors, and clinical research organizations (CROs), highlight significant barriers to collaboration while offering concrete steps to overcome them.

The feedback provides a picture of an industry grappling with communication gaps, staffing shortages, and technology overload. However, the findings also point to practical solutions that could transform these strained relationships and accelerate the development of new treatments.

While nearly two-thirds of sponsors say their relationship with sites is "collaborative," just about half of sites say the same about sponsors, and only 31 percent characterise their relationship with CROs as such. The survey also found efficiency gaps - sites reporting they must copy or transcribe data between systems about 60 percent of the time, and the same percentage saying they frequently enter identical data into multiple systems. These duplications can lead to data errors and trial delays.

FLERE HISTORIER FRA BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Asia

The Race to Build Singapore's Biotech Unicorns

MIRXES, known for its work in early cancer detection and backed by A*STAR and the National University of Singapore, became Southeast Asia's first biotech unicorn when it listed on the Hong Kong Exchange in 2025.

time to read

5 mins

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

"Neuroinflammation is not only a hallmark of Alzheimer's disease but a key pathological feature in other neurodegenerative disorders"

As dementia becomes the leading cause of death in Australia and Alzheimer’s disease continues to affect millions worldwide, the urgency for fundamentally new treatment strategies has never been clearer.

time to read

4 mins

BioSpectrum Asia Feb 2026

BioSpectrum Asia

Leprosy Isn't Over: South-East Asia's Unfinished Fight

As we commemorate World Leprosy Day on January 25, the global community is oldest diseases-has not yet been consigned to history.

time to read

2 mins

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

"Absence of a widespread infectious disease emergency in 2025 has hindered progress in combating AMR"

After decades of incremental antibiotic innovation, antimicrobial resistance (AMR) is outpacing our ability to respond, and 2026 may mark a breaking point.

time to read

5 mins

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

The Strategic Rise of India's Deep-Science Economy

India is emerging as a powerful hub for deep science and biotechnology, driven by favourable geopolitics, a large domestic market, strong pharmaceutical and chemicals infrastructure, and supportive government policies.

time to read

4 mins

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Japan strengthening biopharma capabilities

Asia's biopharma landscape is shifting rapidly toward innovation, with countries such as South Korea, Singapore, India, and Taiwan advancing R&D capabilities.

time to read

7 mins

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Cancer Diagnosis, Accelerated by AI

Cancer remains a leading cause of death worldwide, with Asia bearing a disproportionate burden.

time to read

13 mins

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Beyond Companion Diagnostics: How Biomarkers and Digital Technologies Will Reshape Oncology Care in Asia by 2026

The oncology landscape in Asia stands at a critical juncture.

time to read

5 mins

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Pharma M&A set to boom in 2026

After years of unspectacular Mergers and Acquisitions (M&A) activity, 2025 recorded some of the largest pharma deals.

time to read

3 mins

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Seeing Opportunity in Ophthalmology

Asia-Pacific is emerging as one of the most active regions for ophthalmology innovation. In recent months, a wave of cross-border partnerships and licensing deals has underscored both the scale of unmet need in eye disease and the region's growing ambition to play a larger role in treatment development. From glaucoma and retinal disorders to dry eye disease and childhood myopia, companies across pharma, biotech, and medtech are increasingly accelerating clinical progress.

time to read

6 mins

BioSpectrum Asia Jan 2026

Listen

Translate

Share

-
+

Change font size